Management of the Adult with Congenital Adrenal Hyperplasia
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Congenital adrenal hyperplasia (CAH), most commonly due to 21-hydroxylase deficiency (21OHD), has been studied by pediatric endocrinologists for decades. Advances in the care of these patients have enabled many of these children to reach adulthood. In contrast to the course and management of the disease in childhood, little is known about CAH in adults. In many patients, the proclivity to salt-wasting crises decreases. Linear growth ceases, and reproductive function becomes an issue. Most importantly, management must minimize the potential for long-term consequences of conventional therapies. Here we review the existing literature regarding comorbidities of adults with 21OHD, goals of treatment, and approaches to therapy, with an emphasis on need for improved management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649 · cited 2×
“Furthermore, the adrenal gland lacks 17β-HSD3, the enzyme responsible for reduction of AD to T in the testis, but contains AKR1C3 (17β-HSD5) [7], which has weak activity in catalyzing this reaction [10].”
Wu, L., Einstein, M., Geissler, W. M., Chan, H. K., Elliston, K. O., & Andersson, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31480-7 · Cited by 437 · cited 1×
“by efficiently converting T to AD [23], achieves a pseudoequilibrium in intact cells with 1-2% T generated from AD and increases the apparent potency of AD as an androgen in model systems [24].”
Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase.
Jenkins, E. P., Andersson, S., Imperato-McGinley, J., Wilson, J. D., & Russell, D. W. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115574 · Cited by 395
The backdoor pathway to dihydrotestosterone
Auchus, R. J. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.09.004 · Cited by 347 · cited 1×
“Via this pathway, DHT is formed without the intermediacy of T or AD [14].”
Self-citationArlt, W., Walker, E. A., Draper, N., Ivison, H. E., Ride, J. P., Hammer, F., Chalder, S. M., Borucka-Mankiewicz, M., Hauffa, B. P., Malunowicz, E. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16503-3 · Cited by 345
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344 · cited 1×
“This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.”
Turgeon, D., Carrier, J.-S., Lévesque, E., Hum, D. W., & Bélanger, A. (2001) · Endocrinology · doi:10.1210/endo.142.2.7958 · Cited by 333 · cited 1×
“In liver and skin, 5α-reductase type 1 [25] further activates T to DHT, but T and DHT are also substrates for UDP-glucuronyl transferases (UGTs), which conjugate active androgens and their metabolites for excretion in the urine [26].”
Joint LWPES/ESPE CAH Working Group (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020611 · Cited by 332
Modified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322 · cited 1×
“Sustained-release hydrocortisone preparations administered once daily with promising pharmacokinetics have been developed [32], but these products currently are not widely available.”
Barnes, R. B., Rosenfield, R. L., Ehrmann, D. A., Cara, J. F., Cuttler, L., Levitsky, L. L., & Rosenthal, I. M. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.5.7962325 · Cited by 304 · cited 4×
“In addition, women with 21- OHD often develop a secondary polycystic ovary syndrome (PCOS), such that androgens and 17-OHP also derive from the ovaries and persists even after adrenal suppression [40].”
InfluentialBiswas, M. G., & Russell, D. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15959 · Cited by 224 · cited 1×
“Androsterone reduction by 17β-HSD enzymes yields 5αandrostane-3α, 17β-diol (Adiol), which is metabolized by oxidative 3α-HSD enzymes such as 17β-HSD6 (RODH) [13] to DHT (Figure 2(b)).”
Lindsay, J. R., Nansel, T., Baid, S., Gumowski, J., & Nieman, L. K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1058 · Cited by 210 · cited 1×
“These health problems are similar to those maladies associated with poor quality of life in patients with adrenal insufficiency [38] or cured Cushing’s disease [39] after long-term followup.”
Nordenskjöld, A., Holmdahl, G., Frisén, L., Falhammar, H., Filipsson, H., Thorén, M., Janson, P. O., & Hagenfeldt, K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0556 · Cited by 205 · cited 2×
“The reasons for their not attempting pregnancy include vaginal abnormalities, such as inadequate caliber for coitus or strictures following repair [43] and dyspareunia [42].”
Merke, D. P., Keil, M. F., Jones, J. V., Fields, J., Hill, S., & Cutler, G. B. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6462 · Cited by 190
Casteràs, A., De Silva, P., Rumsby, G., & Conway, G. S. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03563.x · Cited by 190 · cited 3×
“Restoration of fertility in women [46, 60] and men [61] with 21-OHD after bilateral or unilateral adrenalectomy, respectively, has been observed and should be considered as an alternative approach.”
Wilson, J. D., Auchus, R. J., Leihy, M. W., Guryev, O. L., Estabrook, R. W., Osborn, S. M., Shaw, G., & Renfree, M. B. (2003) · Endocrinology · doi:10.1210/en.2002-220721 · Cited by 172 · cited 1×
“Alternative routes to 5α-reduced, 19-carbon steroids have been described in other species [11, 12].”
Self-citationHigh prevalence of reduced fecundity in men with congenital adrenal hyperplasia
Reisch, N., Flade, L., Scherr, M., Rottenkolber, M., Pedrosa Gil, F., Bidlingmaier, M., Wolff, H., Schwarz, H.-P., Quinkler, M., Beuschlein, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1414 · Cited by 170
Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1350 · Cited by 167 · cited 3×
“In fact, children [29] and adults [30] with 21-OHD are prone to develop hypertension, prompting reduction or rarely discontinuation of mineralocorticoid dosing, or the paradoxical need for antihypertensive drugs plus fludrocortisone acetate.”
Homma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I., Tajima, T., Takeda, R., Fukami, M., & Ogata, T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2460 · Cited by 153
Fractures and bone mineral density in adult women with 21-hydroxylase deficiency
Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0744 · Cited by 151 · cited 1×
“Reduced bone mineral density has been found in 21-OHD in most studies [35, 36], but the degree is moderate, and frank osteoporosis is uncommon.”
Claahsen-van der Grinten, H. L., Otten, B. J., Takahashi, S., Meuleman, E. J. H., Hulsbergen-van de Kaa, C., Sweep, F. C. G. J., & Hermus, A. R. M. M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1311 · Cited by 139
Nakamura, Y., Hornsby, P. J., Casson, P., Morimoto, R., Satoh, F., Xing, Y., Kennedy, M. R., Sasano, H., & Rainey, W. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2374 · Cited by 129 · cited 2×
“Furthermore, the adrenal gland lacks 17β-HSD3, the enzyme responsible for reduction of AD to T in the testis, but contains AKR1C3 (17β-HSD5) [7], which has weak activity in catalyzing this reaction [10].”
Shackleton, C., Marcos, J., Arlt, W., & Hauffa, B. P. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30171 · Cited by 104
Reisch, N., Scherr, M., Flade, L., Bidlingmaier, M., Schwarz, H.-P., Müller-Lisse, U., Reincke, M., Quinkler, M., & Beuschlein, F. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1929 · Cited by 92 · cited 8×
“Treatment of the TARTs with intensified glucocorticoid replacement may cause regression and restoration of normal sperm counts [55].”
InfluentialExtraadrenal 21-Hydroxylation by CYP2C19 and CYP3A4: Effect on 21-Hydroxylase Deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1174 · Cited by 91
Mapes, S., Corbin, C. J., Tarantal, A., & Conley, A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.6105 · Cited by 86
Sciannamblo, M., Russo, G., Cuccato, D., Chiumello, G., & Mora, S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2823 · Cited by 82 · cited 1×
“Reduced bone mineral density has been found in 21-OHD in most studies [35, 36], but the degree is moderate, and frank osteoporosis is uncommon.”
Mahendroo, M., Wilson, J. D., Richardson, J. A., & Auchus, R. J. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.04.009 · Cited by 75 · cited 1×
“Alternative routes to 5α-reduced, 19-carbon steroids have been described in other species [11, 12].”
Self-citationOutcome of bilateral adrenalectomy in congenital adrenal hyperplasia: one unit’s experience
Ogilvie, C. M., Rumsby, G., Kurzawinski, T., & Conway, G. S. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02096 · Cited by 55 · cited 1×
“Restoration of fertility in women [46, 60] and men [61] with 21-OHD after bilateral or unilateral adrenalectomy, respectively, has been observed and should be considered as an alternative approach.”
Nguyen, A. D., Mapes, S. M., Corbin, C. J., & Conley, A. J. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0337 · Cited by 38 · cited 1×
“The zona fasciculata cells, which contain 3β-HSD2 activity, also contain CYP17A1; however, these cells have low 17,20lyase activity because expression of the important cofactor protein cytochrome b5 (b5) is low [8, 9].”
Cited by
Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
“Higher bedtime doses (reverse circadian regimen) are commonly used in an attempt to improve androgen control (11, 26, 27), with 84% at baseline in this study; however, evening glucocorticoid administration has the potential for adverse metabolic actions (28) and insomnia.”
MethodJenkins-Jones, S., Parviainen, L., Porter, J., Withe, M., Whitaker, M. J., Holden, S. E., Morgan, C. L., Currie, C. J., & Ross, R. J. M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0895 · Cited by 85
Non-classic congenital adrenal hyperplasia
Witchel, S. F. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.010 · Cited by 52
Nordenström, A. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834810a4 · Cited by 42
Metadata
- Authors
- Auchus, R. J.
- Venue
- International Journal of Pediatric Endocrinology
- Published
- 2010
- Volume
- 2010
- Pages
- 1-9
- ISSN
- 1687-9848 (ISSN-L)
- 1687-9856
- OpenAlex
- W2054115645
- Cited by
- 17
- References
- 31
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.